Vaxcyte, Inc. PCVX Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$320.62M-128% | -$246.51M-79.8% | -$212.83M-106% | -$166.57M-29.4% | -$140.72M-48.1% | ||
| $2.95M-0.3% | $7.5M+162% | $3.06M+71.4% | $2.88M+113% | $2.96M+196% | ||
| $37.96M+24.0% | $36M+47.7% | $35.31M+66.0% | $36.93M+71.3% | $30.62M+73.7% | ||
| -$269K+99.1% | $21.67M-30.8% | —— | —— | -$29.16M-614% | ||
| -$15.57M-254% | $7.3M+178% | —— | —— | -$4.39M-0.9% | ||
| $8.74M+483% | $9.55M+190% | $0-100% | $6.67M— | $1.5M-69.8% | ||
| $2.91M+51.6% | $2.3M+19.9% | $2.13M-21.1% | $2.11M-0.8% | $1.92M-8.3% | ||
| -$1.29M-108% | $33.14M-23.2% | —— | —— | $16M+987% | ||
| -$280.63M-68.8% | -$224.83M-102% | -$143.31M-136% | -$121.17M+0.2% | -$166.27M-4.5% | ||
| $2.11M-61.2% | $2.65M-34.0% | $3.82M-22.7% | $1.81M-76.7% | $5.42M-4.5% | ||
| $584.13M+85.7% | $292.65M-64.1% | $255.32M-79.3% | $349.05M-0.5% | $314.49M-54.3% | ||
| $24.88M-4.5% | $68.22M+178% | $38.33M+44.6% | $42.07M+340% | $26.07M+309% | ||
| -$233.41M-289% | $115.13M+121% | $121.17M+113% | $77.74M+197% | $123.32M+127% | ||
| $9.03M+49.3% | $3.42M— | $306K-99.7% | $3.24M-97.0% | $6.05M— | ||
| $9.3M+75.7% | $1.01M-7.2% | $3.98M-57.4% | $717K+26.9% | $5.29M+60.0% | ||
| $601.58M+79,160% | $2.41M-50.9% | -$3.67M-100% | $2.52M-97.7% | $759K-99.9% | ||
| -$664K-157% | $176K-87.0% | $291K+105% | $800K— | $1.17M-80.7% | ||
| $86.88M+312% | -$107.12M+83.8% | -$25.52M-105% | -$40.11M+56.8% | -$41.03M-119% | ||
| $3.11M-36.7% | $2.76M-76.3% | $2.26M-62.9% | $4.49M-54.8% | $4.91M-55.3% | ||
| -$2.2M-133% | $1.66M+115% | $789K-87.8% | $25.71M— | $6.62M— | ||
| -$15.02M-4.2% | $6.23M-25.4% | —— | —— | -$14.42M-80.9% | ||
| $54.85M+578% | —— | $19.99M— | $35.13M— | $8.09M+116% | ||
| -$1.29M-108% | $33.14M-23.2% | —— | —— | $16M+987% | ||
| $0-100% | $34.8M-23.2% | —— | —— | $17.58M— | ||
| $16.88M+157% | $11.54M+159% | $11.32M+63.4% | $10.48M+60.1% | $6.55M-23.6% | ||
| $8.74M+483% | $9.55M+190% | $0-100% | $6.67M— | $1.5M-69.8% | ||
| $2.91M+51.6% | $2.3M+19.9% | $2.13M-21.1% | $2.11M-0.8% | $1.92M-8.3% | ||
| $12.69M-40.5% | $5.77M-77.8% | $8.22M-75.2% | $7.94M-74.5% | $21.33M+234% | ||
| $340.63M-22.3% | $347.97M+32.0% | $350.2M+6.9% | $394.48M+31.6% | $438.49M+81.0% | ||
| $24.88M-4.5% | $68.22M+178% | $38.33M+44.6% | $42.07M+340% | $26.07M+309% | ||
| —— | $0-100% | $0-100% | $0-100% | $0-100% | ||
| $601.85M— | —— | $0-100% | $0-100% | $0-100% | ||
| $9.03M+49.3% | $3.42M-42.9% | $306K-97.4% | $3.24M— | $6.05M— | ||
| $6.34M+63.1% | $1.97M-74.2% | $2.1M+739% | $0— | $3.89M-71.7% | ||
| -$1.29M-108% | $33.14M-23.2% | —— | —— | $16M+987% | ||
| -$282.73M-64.7% | -$227.49M-97.1% | -$147.13M-124% | -$122.98M+4.8% | -$171.7M-4.2% | ||
| -$282.73M-64.7% | -$227.49M-97.1% | -$147.13M-124% | -$122.98M+4.8% | -$171.7M-4.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Vaxcyte, Inc. generate?
- Vaxcyte, Inc. (PCVX) generated -$769.9M in operating cash flow over the trailing twelve months.
- What is Vaxcyte, Inc.'s free cash flow?
- After $10.4M of capital expenditures, Vaxcyte, Inc.'s free cash flow was -$780.3M over the trailing twelve months, down 61.9% year over year.
- Where does Vaxcyte, Inc.'s cash flow data come from?
- Every line is extracted from Vaxcyte, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.